Dr. John Cush RheumNow
4 years 4 months ago
Large Granular Lymphocyte Leukemia rarely assoc w/ #RA. LGL accounts for 2-5% of lymphoprolif. disorders; often assoc w/ Autoimmune Dz (mostly RA). RA w/ LGL presents with leukopenia, anemia, splenomegaly, onset after mean 6 yrs of RA https://t.co/AIz2edHDXp https://t.co/DoHKm3KS7d
Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.
Dr. John Cush RheumNow
4 years 4 months ago
Machine Learning helps predict RA relapse: data from KURAMA, 210 RA pts (150 achieved remission; 60 relapsed). Using clinical, lab and US findings, ML identified US findings in wrist and MTP predictors of relapse https://t.co/9rhctim4Mh https://t.co/iK3JudOMsC
Dr. John Cush RheumNow
4 years 4 months ago
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign?
https://t.co/s5duGwoWeo https://t.co/lTqBKBHg0g
Dr. John Cush RheumNow
4 years 4 months ago
Multimorbidity Burden in Rheumatoid Arthritis
Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.
https://t.co/vgC1dCA7kZ https://t.co/fLOaa1PDGU
Dr. John Cush RheumNow
4 years 4 months ago
Rising Incidence of Systemic Lupus Erythematosus
Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.
https://t.co/LCDmVS5UVb https://t.co/f3z6BlURkj
This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.
- Microbiome in Spondyloathritis - Jose Scher, MD
- Axial Psoriatic Arthritis - Philip Mease, MD
- Juvenile Spondyloathritis - Pamela Weiss, MD
Dr. John Cush RheumNow
4 years 4 months ago
The global axial spondyloarthritis (therapeutics) market was estimated to be at $1.87 Billion in 2021, and is expected to grow to $7.9 billion by 2032 https://t.co/P9TUUBoneM https://t.co/qfBdkvCdru
Dr. John Cush RheumNow
4 years 4 months ago
Tuesday Night Rheumatology: Spondyloarthritis Spectrum https://t.co/4QW8dNGJQq
Leonard Calabrese LCalabreseDO
4 years 4 months ago
@RheumNowNews has already taken a shot at this but let us try :
HOW MANY RITUXIMAB pts do you have on EVUSHELD pre exposure prophylaxis for #COVID19 @CCalabreseDO @PaulSaxMD @philipcrobinson @JYazdanyMD @DrPujaMehta1 @jeffsparks @zach_wallace_md @alhkim
The COVID-19 Global Rheumatology Alliance rheum_covid
4 years 4 months ago
And now the paper that no one can find even if they are looking for it. On the relationship between disease activity and glucocorticoid disease.
https://t.co/aT8I0jwQOJ
@rheum_covid @ARD_BMJ https://t.co/7ntGLPdypJ
Arth and Rheum Assoc ARARheum
4 years 4 months ago
Dr. Robert Rosenberg, a founding physician of Arthritis and Rheumatism Associates, is retiring after 44 years effective 5/31/22. ARA extends our deepest gratitude and sincerest thanks for his decades of service and exceptional patient care. We wish him well in his retirement. https://t.co/mYQODUk5VY
